Hemophilia description : An inherited blood disorder, hemophilia occurs when the blood does not clot normally. This eMedTV article provides an overview of hemophilia, including information about how it is diagnosed and treated, and offers links to additional information.

f)Mild hemophilia may not cause any symptoms for years, so treatment may not be needed.
 
Moderate hemophilia may require treatment only when bleeding occurs. People with moderate hemophilia should learn to recognize the signs and symptoms of bleeding so that they can get medical attention as quickly as possible. They may also receive hemophilia treatment to prevent bleeding that could occur when participating in some activities.
 
Severe hemophilia usually requires long-term or shorter-term preventive therapy to prevent bleeding that could cause permanent damage to joints, muscles, or other parts of the body. However, some people with severe hemophilia receive treatment only when bleeding occurs.

e) hemophilia is a X-linked recessive pattern, where the mutated gene is located on the X chromosome. This results in a higher frequency of occurrence in males, who only have on X chromosome; since females havetwo X chromosomes, they need two mutated genes to have the disorder, or else they become carriers. Carriers rarely have symptoms, 10 percent have mild problems with bleeding.

g) Blood donors are now screened, and commercial products are now heat-treated to kill the viruses. Genetic screening can identify carriers of hemophilia, and the status of fetuses can be now be ascertained early in pregnancy.

h) Thanks to the development of clotting factor products, most people with hemophilia can look forward to a near-normal life span.
There are three main complications that may develop in people with hemophilia:
* Joint destruction – Multiple episodes of bleeding into joints can result in severe joint damage.
* Blood-borne infection – Blood testing and purification techniques have improved markedly over the years. It is now exceedingly rare for or HIV infections to be transmitted through blood products.
* Development of inhibitor antibodies – People who are treated with clotting factors can develop inhibitor antibodies. These are proteins that decrease the effectiveness of the clotting treatment. When this occurs, treatment can become complicated and expensive